All In Biotech

NDA 021583 · Pfizer

Depo-Subq Provera 104

Medroxyprogesterone Acetate · Subcutaneous

Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Dec 17, 2004

Approved uses

3

Original approval plus efficacy supplements

Registered trials

183

47 Phase 3, 16 recruiting

FAERS reports

10,076

8,739 serious, 311 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: LOSS OF BONE MINERAL DENSITY • Women who use depo-subQ provera 104 may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible [see Warnings and Precautions (5.1) ] . • It is unknown if use of depo-subQ provera 104 during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life [see Warnings and Precautions (5.1) ] . • Depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate [see Indications and Usage (1) and Warnings and Precautions (5.1) ] . WARNING: LOSS OF BONE MINERAL DENSITY See full prescribing information for complete boxed warning . • Women who use...

What it is approved for

From the label in effect Dec 18, 2025.

Depo-subQ provera 104 is indicated in females of reproductive age for: • Prevention of pregnancy and • Management of endometriosis-associated pain. Depo-subQ provera 104 is a progestin that is indicated in females of reproductive age for: • Prevention of pregnancy. ( 1 ) • Management of endometriosis-associated pain. ( 1 ) Limitations of Use : Use of depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate. ( 1 , 5.1 ) Limitations of Use : The use of depo-subQ provera 104 is not recommended as a long-term (i.e., longer than 2 years) birth control method or medical therapy for endometriosis-associated pain unless other options are considered inadequate [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ].

Mechanism: Depo-subQ provera 104 inhibits the secretion of gonadotropins, which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect. Suppression of serum estradiol concentrations is likely to be responsible for the therapeutic effect on endometriosis-associated pain.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • DEPO-SUBQ PROVERA 104 · MEDROXYPROGESTERONE ACETATE 104MG/0.65ML · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Medroxyprogesterone" as an intervention, any sponsor and status, largest first.

All 183 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • breast cancer female2,993
  • breast cancer1,819
  • meningioma844
  • breast cancer metastatic434
  • drug ineffective309
  • off label use235
  • oestrogen receptor assay positive215
  • pain200
  • ovarian cancer186
  • nausea183
  • progesterone receptor assay positive178
  • fatigue167

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,186
2005855
2006782
2007197
2008300
2009481
20101,841
2011504
2012280
201389
201472
2015123
2016122
2017113
2018153
2019217
2020272
2021212
2022200
2023240
2024347
2025791
2026699

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Depo-Subq Provera 104 (Medroxyprogesterone Acetate)

2024 spending

$53K

Beneficiaries

344

927 claims

Per beneficiary

$154

$83.05 per unit

View as table
YearSpending
2020$103,121
2021$35,629
2022$28,222
2023$31,665
2024$52,877

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,600 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.